Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Pharmaceutical Market in China: The Year of the Crab

This article was originally published in Start Up

Executive Summary

Cancer has overtaken respiratory and infectious diseases as the leading cause of mortality in both urban and rural China, creating an enormous demand for anti-cancer pharmaceuticals. According to "China Anti-Cancer Drug Market", a report distributed by FDC-Windhover Elsevier, the sales growth of anti-cancer drugs in China spiked from 11.1% in 2006 to 25.4% in 2007, at which point the market was worth $3.5 billion.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel